Spectranetics Launches Tapas Catheter for Drug Delivery in Peripheral Vessels


October 11, 2012

The Tapas catheter is manufactured by ThermopeutiX Inc. and distributed by Spectranetics Corp. It is the first drug infusion system to provide a versatile solution using a single adjustable and repositionable catheter to deliver any physician-specified drug or diagnostic agent. Its dual occlusion balloon design allows for precise targeting of the treatment area, delivery and dwell time of the drug, and aspiration to minimize systemic effects.

The Tapas catheter provides physicians a unique option for localized drug delivery to help address the growing clinical need for new treatments for peripheral arteries. According to The Sage Group, peripheral artery disease (PAD) of the lower extremities affects approximately 17 million people in the United States1, although many patients are unaware of their condition or the seriousness of it. PAD patients have an increased risk for cardiovascular disease and a significantly increased risk of amputation, disability and diminished quality of life.

Spectranetics Corp. launched the Tapas catheter in the U.S. market at the 2012 Vascular Interventional Advances (VIVA) conference in Las Vegas.

For more information: www.vivapvd.com or www.spectranetics.com